Hormonal intervention in breast cancer: Past, present, and future

Annals of the New York Academy of Sciences

Volumn 784, Issue , 1996, Pages 427-432

  Osborne, Michael P ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIESTROGEN; AROMATASE INHIBITOR; FULVESTRANT; GESTAGEN; GONADORELIN AGONIST; TAMOXIFEN; TESTOSTERONE;

BREAST CANCER; CANCER HORMONE THERAPY; CONFERENCE PAPER; FEMALE; HUMAN; OVARIECTOMY;

EID: 0029946172     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb16257.x     Document Type: Article

References (31)

1. BEATSON, G. T. 1896. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet ii: 104-107; 162-165.
2. BEATSON, G. T. 1901. The treatment of the cancer of the breast by oophorectomy and thyroid extract. Br. Med. J. ii: 1145-1148.
3. SCHINZINGER, A. 1889. Ueber carcinoma mamma. Zentralbl. Chir. 16: 55.
4. HUGGINS, C. & D. M. BERGENSTAL. 1952. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 12: 134.
5. HUGGINS, C. & T. L. Y. DAO. 1953. Adrenalectomy and oophorectomy in the treatment of advanced carcinoma of the breast. J. Am. Med. Assoc. 151: 1388-1394.
6. LUFT, R. & H. OLIVECRONA. 1953. Hypophysectomy in man. J. Neurosurg. 10: 301-316.
7. ULRICH, P. 1939. Testosterone (hormone male) et son role possible dans le traitment de certains cancers du sein. Int. Union Cancer 4: 377.
8. HADDOW, A., J. M. WATKINSON & E. PATTERSON. 1944. Influence of synthetic estrogens upon advanced malignant disease. Br. Med. J. ii: 393-398.
9. GORSKI, J. 1992. Remembrance: the introduction of molecular biology and receptors into the study of hormone action. Endocrinology 131: 1583-1584.
10. JENSEN, E. V. & H. I. JACOBSON. 1960. Fate of steroid estrogens in target tissues. In Biological Activities of Steroids in Relation to Cancer. G. Pincus & E. P. Vollmer, Eds.: 161-168. Academic Press. New York.
11. GLASCOCK, R. F. & W. G. HOEKSTRA. 1959. Selective accumulation of tritium-labeled hexosterol by the reproductive organs of immature female goats and sheep. Biochem. J. 72: 673-682.
12. FOLCA, P. J., R. F. GLASCOCK & W. T. IRVINE. 1961. Studies with tritium-labeled hexestrol in advanced breast cancer. Lancet ii: 796-798.
13. HARPER, M. J. K. & A. L. WALPOLE. 1966. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature (London) 212: 87.
14. COLE, M. P., C. T. A. JONES & I. D. H. TODD. 1971. A new antiestrogenic agent in late breast cancer: an early appraisal of ICI 146,474. Br. J. Cancer 25: 270.
15. EARLY BREAST CANCER TRIALISTS COLLABORATIVE GROUP. 1989. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15.
16. JORDAN, V. C. 1976. Effect of tamoxifen (ICI 146,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur. J. Cancer 12: 419-423.
17. POWLES, T., J. HARDY, S. ASHLEY et al. 1989. Chemoprevention of breast cancer. Breast Cancer Res. Treat. 14: 23-31.
18. GRIFFITHS, G. T., T. C. HALL, S. SABA et al. 1973. Preliminary trial of aminoglutethamide in breast cancer. Cancer 32: 31-37.
19. SANTEN, R. J., A. LIPTON & J. KENDALL. 1974. Successful medical adrenalectomy with aminoglutethamide: role of altered drug metabolism, J. Am. Med. Assoc. 230: 1661-1665.
20. LOBER, J., C. ROSE, M. SALIMTSCHIK & M. T. MOURIDSEN. 1981. Treatment of advanced breast cancer with progestins. Acta Obstet. Gynecol. Scand. Suppl. 101: 39-46.
21. NICHOLSON, R. I., K. J. WALKER, A. TUKES et al. 1985. Endocrinological and clinical aspects of LHRH action (ICI 118,630) in hormone-dependent breast cancer. J. Steroid Biochem. 23: 843-847.
22. BRODIE, A. H. M., W. C. SCHWARZEL, A. A. SHAIKH et al. 1991. The effect of an aromatase inhibitor 4-hydroxy-4-androstene-3,7-dione on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 129: 1684-1695.
23. WAKELING, A. E., M. DUKES & J. A. BOWLER. 1991. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51: 3867-3873.
24. HOWELL, A., D. DEFRIEND, J. ROBERTSON et al. 1995. Response to a specific antiestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29-30.
25. SWANECK, G. E. & J. FISHMAN. 1988. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intracellular localization. Proc. Natl. Acad. Sci. U.S.A. 85: 7831-7835.
26. TELANG, N. T., A. SUTO, G. Y. C. WONG et al. 1992. Induction by estrogen metabolite 16α-hydroxyestrone of genotoxic damage and aberrant hyperproliferation in mouse mammary epithelial cells. J. Natl. Cancer Inst. 84: 634-638.
27. OSBORNE, M. P., H. L. BRADLOW, G. Y. C. WONG & N. T. TELANG. 1993. Up-regulation of estradiol C16α-hydroxylation in human breast tissue; a potential biomarker for breast cancer risk. J. Natl. Cancer Inst. 85: 1917-1920.
28. BRADLOW, H. L, J. J. MICHNOVICZ, N. T. TELANG et al. 1991. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12: 1571-1574.
29. TIWARI, R. K., L. GUO, H. L. BRADLOW et al. 1994. Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J. Natl. Cancer Inst. 86: 126-131.
30. SUTO, A., H. L. BRADLOW, G. Y. C. WONG et al. 1993. Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res. Treat. 27: 193-202.
31. BRADLOW, H. L. & J. J. MICHNOVICZ. 1989. A new approach to the prevention of breast cancer. Proc. R. Soc. Edinb. 95B: 77-86.